554 related articles for article (PubMed ID: 26721620)
1. Challenges in the development of therapeutics for narcolepsy.
Black SW; Yamanaka A; Kilduff TS
Prog Neurobiol; 2017 May; 152():89-113. PubMed ID: 26721620
[TBL] [Abstract][Full Text] [Related]
2. Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy.
Szabo ST; Thorpy MJ; Mayer G; Peever JH; Kilduff TS
Sleep Med Rev; 2019 Feb; 43():23-36. PubMed ID: 30503715
[TBL] [Abstract][Full Text] [Related]
3. Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy.
Black SW; Morairty SR; Fisher SP; Chen TM; Warrier DR; Kilduff TS
Sleep; 2013 Mar; 36(3):325-36. PubMed ID: 23449602
[TBL] [Abstract][Full Text] [Related]
4. Transgenic Archaerhodopsin-3 Expression in Hypocretin/Orexin Neurons Engenders Cellular Dysfunction and Features of Type 2 Narcolepsy.
Williams RH; Tsunematsu T; Thomas AM; Bogyo K; Yamanaka A; Kilduff TS
J Neurosci; 2019 Nov; 39(47):9435-9452. PubMed ID: 31628177
[TBL] [Abstract][Full Text] [Related]
5. Narcolepsy and the hypocretin system--where motion meets emotion.
Siegel JM; Boehmer LN
Nat Clin Pract Neurol; 2006 Oct; 2(10):548-56. PubMed ID: 16990828
[TBL] [Abstract][Full Text] [Related]
6. Emerging treatments for narcolepsy and its related disorders.
Nishino S; Okuro M
Expert Opin Emerg Drugs; 2010 Mar; 15(1):139-58. PubMed ID: 20166851
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of narcolepsy medications.
Gowda CR; Lundt LP
CNS Spectr; 2014 Dec; 19 Suppl 1():25-33; quiz 25-7, 34. PubMed ID: 25403789
[TBL] [Abstract][Full Text] [Related]
8. [Advances in the diagnosis and treatment of narcolepsy-cataplexy syndrome].
de Vicente Alvarez-Manzaneda EE
Rev Neurol; 2008 May 1-15; 46(9):550-6. PubMed ID: 18446698
[TBL] [Abstract][Full Text] [Related]
9. The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions.
Zeitzer JM; Nishino S; Mignot E
Trends Pharmacol Sci; 2006 Jul; 27(7):368-74. PubMed ID: 16766052
[TBL] [Abstract][Full Text] [Related]
10. Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy.
Baier PC; Hallschmid M; Seeck-Hirschner M; Weinhold SL; Burkert S; Diessner N; Göder R; Aldenhoff JB; Hinze-Selch D
Sleep Med; 2011 Dec; 12(10):941-6. PubMed ID: 22036605
[TBL] [Abstract][Full Text] [Related]
11. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system.
Nishino S; Kanbayashi T
Sleep Med Rev; 2005 Aug; 9(4):269-310. PubMed ID: 16006155
[TBL] [Abstract][Full Text] [Related]
12. [Development of a Therapeutic Drug for Narcolepsy].
Irukayama-Tomobe Y; Yanagisawa M
Brain Nerve; 2018 Nov; 70(11):1255-1263. PubMed ID: 30416119
[TBL] [Abstract][Full Text] [Related]
13. [Narcolepsy with cataplexy].
Dauvilliers Y; Arnulf I
Rev Neurol (Paris); 2008; 164(8-9):634-45. PubMed ID: 18805301
[TBL] [Abstract][Full Text] [Related]
14. Narcolepsy: pathophysiology and pharmacology.
Nishino S
J Clin Psychiatry; 2007; 68 Suppl 13():9-15. PubMed ID: 18078360
[TBL] [Abstract][Full Text] [Related]
15. Management of Narcolepsy.
Barateau L; Lopez R; Dauvilliers Y
Curr Treat Options Neurol; 2016 Oct; 18(10):43. PubMed ID: 27549768
[TBL] [Abstract][Full Text] [Related]
16. Animal models of narcolepsy and the hypocretin/orexin system: Past, present, and future.
Tisdale RK; Yamanaka A; Kilduff TS
Sleep; 2021 Jun; 44(6):. PubMed ID: 33313880
[TBL] [Abstract][Full Text] [Related]
17. Narcolepsy in adolescents.
Sullivan SS
Adolesc Med State Art Rev; 2010 Dec; 21(3):542-55, x-xi. PubMed ID: 21302860
[TBL] [Abstract][Full Text] [Related]
18. The development of sleep/wake disruption and cataplexy as hypocretin/orexin neurons degenerate in male vs. female Orexin/tTA; TetO-DTA Mice.
Sun Y; Tisdale R; Park S; Ma SC; Heu J; Haire M; Allocca G; Yamanaka A; Morairty SR; Kilduff TS
Sleep; 2022 Dec; 45(12):. PubMed ID: 35182424
[TBL] [Abstract][Full Text] [Related]
19. Trace Amine-Associated Receptor 1 Agonists as Narcolepsy Therapeutics.
Black SW; Schwartz MD; Chen TM; Hoener MC; Kilduff TS
Biol Psychiatry; 2017 Nov; 82(9):623-633. PubMed ID: 27919403
[TBL] [Abstract][Full Text] [Related]
20. The hypocretin/orexin system in sleep disorders: preclinical insights and clinical progress.
Chow M; Cao M
Nat Sci Sleep; 2016; 8():81-6. PubMed ID: 27051324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
